AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00256529 — intervention group
Intervention type: PROCEDURE
Intervention: EGD with biopsies
Description: All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
Study NCT02568709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
Study NCT02568709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study NCT01906424 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Electrical Spinal Cord Stimulation
Description: A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
Study NCT01906424 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Spinal Cord Stimulation
Description: A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
Study NCT01790113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Univers™
Description: Control
Study NCT01790113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse™ Total Shoulder Replacement
Description: Investigational
Study NCT04144920 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CS: Continuous sitting
Description: Participants were asked to sit continuously throughout the duration of the lab visit.
Study NCT04144920 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HFLD: HIgh frequency, low duration standing breaks
Description: Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
Study NCT04144920 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LFHD: Low frequency, high duration standing breaks
Description: Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
Study NCT02012166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 40 mg
Description: MK-0893 40 mg administered orally in 240 mL of water
Study NCT02012166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 200 mg
Description: MK-0893 200 mg administered orally in 240 mL of water
Study NCT03505190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously (SC).
Study NCT00581100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period.
Study NCT03468998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Socket Grafting with small particle allograft
Description: Small Particle Bone Allograft of 0.25-1.0 mm placed in extraction socket
Study NCT03468998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Socket Grafting with large particle allograft
Description: Large Particle Bone Allograft of 1.0-2.0 mm placed in extraction socket
Study NCT03468998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral ridge augmentation with small particle allograft
Description: Small Particle Bone Allograft of 0.25-1.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
Study NCT03468998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral ridge augmentation with large particle allograft
Description: Large Particle Bone Allograft of 1.0-2.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
Study NCT03906409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant
Description: Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
Study NCT03906409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus
Description: Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
Study NCT02399228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% EISO mouth rinse
Description: A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
Study NCT02798757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Urine samples will be collected for 1HNMR spectroscopies
Study NCT03512730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium brush
Description: a titanium brush will be tested as mechanical decontamination in regenerative treatment of peri-implantitis
Study NCT03512730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic decontamination
Description: Classic decontamination will be performed by means of H2O2 3% and plastic curettes
Study NCT03512730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic decontamination
Description: Classic decontamination will be performed by means of H2O2 3% and plastic curettes
Study NCT02743741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium-177 Octreotate
Description: Radiopharmaceutical
Study NCT02552264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy for the Workplace
Description: Acceptance and Commitment Therapy
Study NCT02552264 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acceptance and Commitment Therapy for the Workplace
Description: Acceptance and Commitment Therapy
Study NCT01688804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to reduce sedentary time delivered via mobile smartphone
Description: The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
Study NCT05299190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga intervention plus TAU
Description: The yoga intervention consists of 8 weekly group sessions. The intervention is based on hatha yoga system. TAU is usual care participants receive from their health care provider
Study NCT05299190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Monitoring plus TAU
Description: clinical monitoring includes bi-weekly 15-20 minute telephone contact with participants. TAU is usual care participants receive from their health care provider.
Study NCT00830531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
Study NCT00830531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline as Placebo
Description: Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
Study NCT03440411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg/daily as oral administration (PO) on days 1-21.
Study NCT03440411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: 4 mg/daily as oral administration (PO) on days 1-21.
Study NCT03440411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg every other day as oral administration (PO) on days 1-28
Study NCT03440411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 50 mg every other day as oral administration (PO) on days 1-28
Study NCT03440411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg as oral administration (PO) on days 1, 8, 15, 22.
Study NCT03440411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg as oral administration (PO) on days 1, 8, 15, 22.
Study NCT01900184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
Study NCT01900184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains magnesium stearate, silica dental type, anhydrous lactose
Study NCT04070703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Go for Exercise & Healthy Aging Project
Description: Exercise and Cognition
Study NCT04070703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Go for Exercise & Healthy Aging Project
Description: Exercise and Cognition
Study NCT04070703 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: The Go for Exercise & Healthy Aging Project
Description: Exercise and Cognition
Study NCT01568879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
Study NCT01568879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gout Disease Management Program
Description: The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
Study NCT04408612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Scales for assessment of symptoms
Description: Medical Research Council Dyspnea scale, the visual analogue scale of dyspnea, Borg scale, modified dictionary of dyspnea, G. Rose questionnaire, Seattle Angina Questionnaire, Framingham criteria for chronic heart failure, the SHOCK scale.
Study NCT03505190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously (SC).
Study NCT01589978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element Plus Coronary Stent System
Description: PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
Study NCT02012166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 1000 mg
Description: MK-0893 1000 mg administered orally in 240 mL of water
Study NCT02012166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally in 240 mL of water
Study NCT02012166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sandostatine®
Description: Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.
Study NCT02012166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.
Study NCT02012166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.
Study NCT01061515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Oxaliplatin
Study NCT01061515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01061515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT01434940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam
Description: . The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
Study NCT04451798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella CP microaxial pump
Description: ramp test
Study NCT03923868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days
Study NCT02177162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education to physiotherapists
Study NCT03981510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D-Transit
Description: 3D transit investigation consists of a small electromagnetic pill and a detector located in a belt around the waist. The pill is swallowed by the participant and the belt is worn until the pill has left the gastrointestinal tract. The method is without any pain and discomfort for the child. The child will visit the hospital the first time to ingest the capsule alongside a standardized meal, and is then free to go home and proceed with daily activities (beside hard exersize) while wearing the belt with the detector. The next day, the child will again visit the hospital to check whether or not the capsule has left the tract - this is done with a computer and software. The children ingesting two capsules will do this with a certain delay.
Study NCT00183248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4
Study NCT00183248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4
Study NCT00183248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study
Study NCT00183248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study
Study NCT00183248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study
Study NCT00183248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study
Study NCT00183248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study
Study NCT00183248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study
Study NCT00183248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor bone marrow stem cell infusion
Description: 2 doses of kidney donor's bone marrow stem cells by IV infusion on Day 5 and sometime between Months 4 and 6
Study NCT00183248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplant
Description: Occurs at study entry
Study NCT00183248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant
Description: Occurs at study entry
Study NCT03790189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subchondral and intra-articular injection of BMC
Description: Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
Study NCT04077502 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation
Study NCT04077502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation
Study NCT03369808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5μg H7N9 Vaccine
Description: The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
Study NCT03369808 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Solution
Description: 0.5ml phosphate buffer solution
Study NCT03369808 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aluminum Hydroxide Adjuvant
Description: 0.5ml aluminum hydroxide adjuvant
Study NCT01589978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.
Study NCT01589978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 antagonist
Description: Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.~* Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)~* Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)~* Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses >100 mg may reduce ticagrelor effectiveness and should be avoided.~* Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)
Study NCT03369808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15μg H7N9 Vaccine
Description: The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
Study NCT03369808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30μg H7N9 Vaccine
Description: The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
Study NCT01500889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group I: Conventional Lateral internal sphincterotomy:
Description: LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
Study NCT01229566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKR-963
Description: 3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
Study NCT01229566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AKR-963
Description: 3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
Study NCT01229566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AKR-963
Description: 3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
Study NCT01690273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobility exercise
Description: 30 minutes, twice a week
Study NCT01690273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobility and elastic resistance exercise
Description: 30 minutes, twice a week each exercises group. (total 1 hour)
Study NCT03009292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: once daily continuous dosing